Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

China Pharma Holdings (CPHI) Non-Current Assets (2016 - 2025)

China Pharma Holdings filings provide 16 years of Non-Current Assets readings, the most recent being $28.7 million for Q4 2025.

  • On a quarterly basis, Non-Current Assets rose 146.64% to $28.7 million in Q4 2025 year-over-year; TTM through Dec 2025 was $64.6 million, a 51.2% increase, with the full-year FY2025 number at $28.7 million, up 146.64% from a year prior.
  • Non-Current Assets hit $28.7 million in Q4 2025 for China Pharma Holdings, up from $13.5 million in the prior quarter.
  • In the past five years, Non-Current Assets ranged from a high of $28.7 million in Q4 2025 to a low of $9.5 million in Q3 2023.
  • Median Non-Current Assets over the past 5 years was $11.5 million (2024), compared with a mean of $12.6 million.
  • Biggest five-year swings in Non-Current Assets: fell 24.53% in 2022 and later soared 146.64% in 2025.
  • China Pharma Holdings' Non-Current Assets stood at $13.6 million in 2021, then fell by 12.81% to $11.8 million in 2022, then dropped by 11.4% to $10.5 million in 2023, then increased by 10.93% to $11.6 million in 2024, then soared by 146.64% to $28.7 million in 2025.
  • The last three reported values for Non-Current Assets were $28.7 million (Q4 2025), $13.5 million (Q3 2025), and $11.1 million (Q2 2025) per Business Quant data.